Lindy Biosciences is developing biotherapeutic drug formulations using its proprietary Microglassification™ technology, enabling patients to self-administer medications at home instead of relying on intravenous infusions in acute care settings. This approach enhances patient comfort and accessibility while facilitating the market entry of more effective therapies.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICFounders
Product
Problem
Many biotherapeutic drugs require administration via intravenous infusions in clinical settings, which can be inconvenient and limit accessibility for patients, particularly those with chronic illnesses. This reliance on acute care settings can also hinder the development and market entry of potentially more effective therapies.
Solution
Lindy Biosciences is developing biotherapeutic drug formulations using its proprietary Microglassification™ technology to enable patient-centric drug delivery. This technology aims to allow patients to self-administer medications at home, rather than requiring them to undergo intravenous infusions in a clinical environment. By providing patients with the option of at-home administration, Lindy Biosciences seeks to improve patient comfort, increase accessibility to medications, and facilitate the development of more effective therapies.
Target Audience
Lindy Biosciences' primary customers are industry partners developing biotherapeutic drug products, as well as patients with chronic illnesses who require frequent medication administration.
Features
- Microglassification™ technology for biotherapeutic drug formulation
- Enables self-administration of medications by patients at home
- Reduces the need for intravenous infusions in acute care settings
- Improves patient comfort and convenience
- Facilitates the market entry of novel therapies